Statistical approaches to assessing the effects of neutralizing antibodies: IFNβ-1b in the pivotal trial of relapsing-remitting multiple sclerosis

Neurology

Volumn 61, Issue 9 SUPPL. 5, 2003, Pages

  Petkau, A John ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON ANTIBODY; INTERFERON ANTIBODY; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ANTIGENICITY; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENCE RISK; STATISTICAL ANALYSIS;

EID: 0242655956     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000092364.87561.f1     Document Type: Conference Paper

References (7)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind placebo-controlled trial. Neurology 1993;43:655-661.
2. Paty DW, Li DKB, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind placebo-controlled trial. Neurology 1993;43:662-667.
3. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
4. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
5. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med 1992;11:1825-1839.
6. Liang KY, Zeger SL. Regression analysis for correlated data. Annu Rev Public Health 1993;14:43-68.
7. Polman C, Kappos L, White R, et al., for the European Study Groups in Interferon beta-1b in Secondary Progressive MS. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003;60:37-43.